النص 🔗
WEBVTT
00:00:00.320 --> 00:00:03.759
Welcome to the Beyond the Purpose podcast.
00:00:04.080 --> 00:00:09.359
Here we focus on the decisions behind healthcare innovation where science meets strategy.
00:00:09.519 --> 00:00:13.679
Hosted by James Cox, CEO of BioTalent, and Jay Webster of Bioex.
00:00:14.160 --> 00:00:23.600
Each episode features conversations with founders and leaders across biotech and pharma about real trade-offs, meaningful signals, and what's coming next.
00:00:23.839 --> 00:00:28.559
No hype, just clear thinking for people building and scaling in life sciences.
00:00:30.719 --> 00:00:35.280
And behind the purpose, we talk to leaders about building companies that truly make a difference.
00:00:35.439 --> 00:00:37.600
And today's guest is doing exactly that.
00:00:37.920 --> 00:00:44.799
Murat Tonoboyo, CEO of Antiverse, is using AI to tackle some of the toughest challenges in drug discovery.
00:00:45.119 --> 00:00:53.759
But this isn't just about technology or funding, it's about purpose, resilience, and what it takes to keep going when the stakes are deeply personal.
00:00:53.920 --> 00:00:55.039
I hope you enjoy.
00:00:56.320 --> 00:00:58.079
Thanks so much for joining us, Murat.
00:00:58.159 --> 00:00:59.840
Uh on Beyond the Purpose.
00:00:59.920 --> 00:01:01.520
Uh, it's great to hear from you.
00:01:01.759 --> 00:01:08.159
Um, I really want to start it around, you know, Antiverse recently closed, it's 9.3 million Series A.
00:01:08.480 --> 00:01:13.920
When that moment finally arrived, what did it actually mean to you personally, kind of beyond the headline?
00:01:14.719 --> 00:01:16.159
Yeah, interesting.
00:01:16.319 --> 00:01:18.640
So we had multiple funding rounds.
00:01:19.040 --> 00:01:29.280
Found the company in 2017, started with a few smaller rounds and uh eventually larger ones, and in total, we raised about 20 million dollars.
00:01:29.599 --> 00:01:35.760
There's this phase of you go at it at full force for a very long time.
00:01:36.000 --> 00:01:40.799
And you know, this fundraising process takes about six months, maybe a bit longer.
00:01:40.959 --> 00:01:43.040
Uh, we had a very, very long one as well.
00:01:43.200 --> 00:01:46.159
And the last month, we began around May.
00:01:46.400 --> 00:01:54.560
And uh, by the time we got the term sheet, I believe it was around September, we got a few of them, you know, and you work through the legals and all of that stuff.
00:01:54.719 --> 00:01:58.719
So by the time we had the money in the bank, it was in January.
00:01:58.879 --> 00:02:01.519
So if you think about it, seven, eight months.
00:02:01.840 --> 00:02:10.800
And I think your body and your emotions don't necessarily adapt immediately back to okay, now we are back to peace mode, let's go back to building.
00:02:11.039 --> 00:02:13.039
It takes a while for that to settle.
00:02:13.120 --> 00:02:21.039
So I've I felt maybe probably it was around April I felt, oh okay, now this is wrapped up.
00:02:21.280 --> 00:02:24.319
Let's let's go go back to building the company.
00:02:24.479 --> 00:02:36.800
Um I think you you build a lot of stress during this period, and that stress stays with you a few months after after the moment of success.
00:02:37.280 --> 00:02:37.759
Definitely.
00:02:37.919 --> 00:02:41.120
I think is it fair to say that you never stop fundraising anyway?
00:02:41.280 --> 00:02:48.319
So even now, like how much of your time are you thinking about the next round and how much are you are you looking at the next fundraiser?
00:02:49.120 --> 00:02:59.199
It never stops, that's true, but I think it definitely takes a much smaller portion of my time.
00:02:59.680 --> 00:03:15.039
So to put into perspective when we officially kicked off the fundraising uh for about a month, we talked with about 300 investors, so it's like that's all you do and nothing else.
00:03:15.360 --> 00:03:19.520
Now I still talk to investors, but I do maybe 10 a month.
00:03:20.400 --> 00:03:27.840
Interesting because I I think there's I mean there's so many investors, there's so many businesses looking for funding, but how do you go about choosing the 300?
00:03:27.919 --> 00:03:33.520
Are you leading that conversation, leading the approach, or like what was your approach to targeting or engaging with investors?
00:03:34.080 --> 00:03:39.280
I think we ran a very uh structured process this time.
00:03:39.520 --> 00:03:49.199
Also, we had the luxury of already, you know, having a large number of investors in our CRM from the previous funding rounds.
00:03:49.360 --> 00:03:57.599
So those relationships were in place, and you know, sometimes investors tell you, oh, you're debit too early, hit these points and then come back.
00:03:57.840 --> 00:04:01.840
So we've been monitoring and nurturing those relationships.
00:04:01.919 --> 00:04:04.960
So you know, we naturally started with those.
00:04:05.199 --> 00:04:18.639
But to to make up the list, most of them came from previous connections through our network, not like fresh connections, but has been connected to in the past.
00:04:19.199 --> 00:04:25.120
And then um, and there are also new funds that didn't exist before that invest in our space.
00:04:25.199 --> 00:04:39.360
So if you look at there are a few websites out there, you can go download a list of investors in your space, and you know, with the tools, you can grade them, not in terms of the fund quality, but in terms of the match.
00:04:39.920 --> 00:04:44.000
For us, it was the criteria of can they lead the series A?
00:04:44.160 --> 00:04:46.399
Can they participate in Series B?
00:04:46.800 --> 00:04:49.360
Uh, do they understand the tech bias space?
00:04:49.519 --> 00:04:51.519
Do they have the pharmaconnections?
00:04:51.680 --> 00:04:55.120
Can they write a check or a term sheet in one month?
00:04:55.360 --> 00:05:08.480
So if you did all of them, then it would be a you know a grade match or a B or a C and D you can so we we had the large lists, we
Load full transcript
kind of prioritized based on that match and then went after.
00:05:09.120 --> 00:05:14.720
I think that, yeah, having a criteria, a scorecard, if you like, to work out who's getting relevant is is important.
00:05:14.879 --> 00:05:33.199
If you cash your mind back to some maybe the first time you look for funding, because I think I personally think the industry has an issue, say yeah, when a business is looking to spin out or you're looking for the first funding round, an investor, a sorry founder or a CEO at that time, but they haven't been on the funding journey, where do they start out?
00:05:33.360 --> 00:05:34.800
How do they create that first list?
00:05:34.879 --> 00:05:42.959
So if you cash your mind back, like what advice would you give to someone who's got the IP, they're excited, they now need that funding partner for the first time?
00:05:43.120 --> 00:05:44.800
What advice would you give them?
00:05:45.199 --> 00:05:48.959
I think finding the names are not that difficult.
00:05:49.519 --> 00:05:58.879
And uh, investors will tell you otherwise, but I think warm introductions are maybe a little bit exaggerated.
00:05:59.199 --> 00:06:06.319
Uh, we had multiple investors coming in and led our previous rounds, completely cold connections.
00:06:06.480 --> 00:06:13.600
Hey, this is Murad, we are antivirus, this is what we do, and they said, Okay, sounds interesting, let's have a deal.
00:06:13.839 --> 00:06:15.519
And that happened time after time.
00:06:15.600 --> 00:06:19.600
So I would definitely do not rule out cold outreach.
00:06:19.839 --> 00:06:23.439
And it's a numbers game, so do not get disheartened.
00:06:23.680 --> 00:06:32.879
I'm part of a founders network, and many of them are financially ahead of us, like they say it's VCs and beyond.
00:06:33.360 --> 00:06:35.600
You go talk to 100 people.
00:06:35.839 --> 00:06:46.160
Uh the averages are so the numbers from these founders are 50, 75, 100, 150 even conversations for a single term sheet.
00:06:46.399 --> 00:06:48.639
So that's a lot of conversations to have.
00:06:48.720 --> 00:06:51.279
And you won't get that many warm introductions either.
00:06:51.439 --> 00:06:55.120
So power of the network, I think in this world.
00:06:55.519 --> 00:06:56.079
Indeed.
00:06:56.240 --> 00:06:58.959
You know, you mentioned before stress.
00:06:59.120 --> 00:07:07.120
Um, I suppose founders uh are expected to project certainty, um, even when the times are kind of ambiguous.
00:07:07.279 --> 00:07:14.079
How do you navigate the kind of the tension or the stress that you mentioned before, especially during difficult periods?
00:07:14.720 --> 00:07:16.000
Stress is real.
00:07:16.160 --> 00:07:21.920
Um, I shared on LinkedIn before that I had a stress-related, I think, collapse.
00:07:22.000 --> 00:07:26.720
Uh, this was back in 2022, I'm gonna say.
00:07:26.959 --> 00:07:31.839
And because you aggregate that stress, and then your body eventually says, Hey, this is a bit too much.
00:07:31.920 --> 00:07:34.160
You you gotta do things differently.
00:07:34.639 --> 00:07:36.480
Internally, we are very open.
00:07:36.639 --> 00:07:42.959
Like, hey, I'm stressed, I'm I'm maybe you know, mildly depressed, I need help.
00:07:43.120 --> 00:07:44.879
And that's a conversation we can have.
00:07:45.040 --> 00:07:50.079
I feel it's emotionally a safe space within the company to have those conversations.
00:07:50.319 --> 00:07:54.000
And I don't think the TV have takes that as a weakness.
00:07:54.079 --> 00:07:57.680
They say, hey, you know, like people approach me and say, Oh, you know what?
00:07:57.839 --> 00:08:02.399
I actually can relate to that because I'm I'm having similar thoughts.
00:08:02.639 --> 00:08:07.839
And we built Antivirus for now nine years, it's gonna be 10 years in six months' time.
00:08:08.800 --> 00:08:18.879
You put so much of your life into it and you make sacrifices along the way, so there's a lot riding on it, and it might be a binary outcome, financially speaking.
00:08:19.199 --> 00:08:23.040
And then you build that team now with about 25-20 of us.
00:08:23.279 --> 00:08:38.080
So if it doesn't work out, you know, these people have to go and you know, there's this feeling of I even it might be subconscious, hey, I'm gonna let people down, or I'm gonna let the mission down, I'm gonna let the investors down.
00:08:38.320 --> 00:08:42.960
And I do this because of my father who passed away to lung cancer.
00:08:43.120 --> 00:08:47.840
So there's that feeling of, uh, am I like letting these people in my life down?
00:08:48.080 --> 00:08:49.360
And there might be other things.
00:08:49.440 --> 00:08:51.840
Hey, where am I gonna find my next salary, right?
00:08:51.919 --> 00:08:55.120
Like what's gonna happen to Antivirus, what's gonna happen to me?
00:08:55.360 --> 00:09:06.720
So those are the things that intellectually you have good answers for, but they might be emotionally not fully resolved.
00:09:06.960 --> 00:09:09.120
That may not sink in yet.
00:09:09.440 --> 00:09:15.519
So one of the stresses were hey, what's gonna happen to these people, right?
00:09:15.600 --> 00:09:23.440
If antivirus falls tomorrow or two months from now, we sponsored many people into the country, they came with their families.
00:09:23.519 --> 00:09:30.399
So it's not just losing your job, it's up uprooting all your family, maybe, and going back somewhere else.
00:09:30.960 --> 00:09:34.799
However, from very early on, we we had the transparency in mind.
00:09:34.879 --> 00:09:46.480
So on Monday meetings, we had the company update all hands on deck, and we tell how much money we have left in the bank and what's the runway and the likelihood of us finding a solution.
00:09:46.799 --> 00:09:49.279
I think it had two benefits.
00:09:49.519 --> 00:09:54.240
One of them it kind of got us together a little bit closer.
00:09:54.799 --> 00:09:57.679
So that was our fight, it united us.
00:09:57.840 --> 00:10:05.759
And then the
second thing, I felt okay, now the ownership of your decision is past you.
00:10:05.840 --> 00:10:08.879
Now you're empowered, you have the information.
00:10:09.120 --> 00:10:17.200
If you think for your family the best decision is to leave right now, thinking that we may not have money six months down the line.
00:10:17.440 --> 00:10:18.720
Your call, right?
00:10:18.879 --> 00:10:19.600
Yeah, yeah.
00:10:19.759 --> 00:10:26.000
I think leading with vulnerability, like the openness, the honesty, something I think is so important.
00:10:26.080 --> 00:10:31.519
Um, and so being able to share that actually creates that psychological safety for your workforce as well.
00:10:31.759 --> 00:10:38.320
Because so many people try and hide things or try and portray one thing when the reality is different, which in my opinion causes that distrust.
00:10:38.480 --> 00:10:42.240
So yeah, learning to lead with vulnerability is is I think so important.
00:10:42.639 --> 00:10:46.879
I mean, interested, there's we we see a lot of decks, we we work with a lot of investors.
00:10:47.039 --> 00:10:50.080
Um, what do you think it was about Antiverse?
00:10:50.320 --> 00:10:58.240
Uh what what were you positioning the business as in terms of your your USP or your your unique piece that someone's going to invest into?
00:10:58.879 --> 00:11:01.279
So I'll I'll mention something about the deck.
00:11:01.519 --> 00:11:08.799
I think in this funding round, funnily enough, I almost never presented the tech.
00:11:09.200 --> 00:11:14.159
I mean, it was there, hey, this is what we do, this is a link interested, book me a meeting.
00:11:14.399 --> 00:11:22.960
But for the people who were really interested in it was hey, let's have a conversation and then tell them a bunch of stories around what we are building.
00:11:23.120 --> 00:11:29.360
I mean, as the companies progress, obviously they look at what you have done as well as what you will do more and more so.
00:11:29.919 --> 00:11:39.600
But um I think the the but people are buying in into the potential of untwivers and how big it can get.
00:11:39.679 --> 00:11:43.519
And I don't mean financially, of course, that's always in mind.
00:11:43.919 --> 00:11:58.000
But um we have the fundamentals of a company in place to be one of the most impactful biotechs of our generation, because this platform can really scale with very, very limited uh obstacles along the way.
00:11:58.399 --> 00:12:04.639
And um, and by impact, I mean the number of people you touch, the number of lives you change or improved.
00:12:05.759 --> 00:12:08.720
We are acting in that space, and it's super exciting.
00:12:08.879 --> 00:12:10.960
There are only a few companies like us in the world.
00:12:11.039 --> 00:12:17.039
So when they look at it, they say, okay, not only that this is like science fiction, it also works.
00:12:17.120 --> 00:12:20.559
We have the case studies, you know, there's something real here.
00:12:21.039 --> 00:12:27.360
Um, you know, you anti-verse is working on targets that have, you know, resisted conventional approaches for decades.
00:12:27.519 --> 00:12:34.720
How do you balance the urgency for patients with the discipline that good science kind of demands?
00:12:35.279 --> 00:12:35.759
Yeah.
00:12:36.080 --> 00:12:41.519
We are still so far away from patients as the way part of the industry is set up.
00:12:41.679 --> 00:12:48.879
So we have our own pipeline, we work on some indications, but let's talk about a discovery partnership.
00:12:49.039 --> 00:12:58.080
Uh, a farmer comes to us, they say, look, this is a target associated, let's say, with colon cancer, and we couldn't discover a molecule against it.
00:12:58.240 --> 00:13:04.879
We design that molecule within a few months and uh give it back to them and they continue testing.
00:13:05.039 --> 00:13:13.840
But on average, that molecule still has another 10, 12 years ahead of it before it reached the market.
00:13:14.639 --> 00:13:21.360
But uh, I mean it is produced at certain quantities that it gets to the clinical trials and shows some efficacy early on.
00:13:21.519 --> 00:13:33.279
So you help people, even maybe in phase one, B to an extent and phase two for sure, to say that hey, you know, we really help in a meaningful phase uh at least some patients.
00:13:33.759 --> 00:13:46.399
But for a um uh a massive success, what you have done right now is gonna only play out 10, 12 years into the future.
00:13:46.879 --> 00:13:53.279
So there is no reason in rushing things to get there a week faster or a month faster.
00:13:53.759 --> 00:14:00.799
You know, making a difference to a patient, whether it is in 10 or 12 years, um, is still an amazing thing.
00:14:00.960 --> 00:14:02.559
You know, I'm driven by that.
00:14:02.720 --> 00:14:10.080
Uh and it, you know, it's fantastic to hear that even though it's not today, um, but certainly it can make a difference.
00:14:11.039 --> 00:14:18.559
What do you see as you know, major disruptive kind of biotech behavior or science that's gonna come up?
00:14:18.720 --> 00:14:24.000
You know, I know I'm putting you on the spot with the question, but you know, what are you seeing from your lens?
00:14:24.159 --> 00:14:25.279
What can make a difference?
00:14:25.440 --> 00:14:29.200
What's gonna disrupt going into uh 2030?
00:14:29.919 --> 00:14:37.120
Yeah, so the timelines I'm not clear, but um sure I'm gonna tell you about the trends that I see.
00:14:37.279 --> 00:14:47.840
So we are part of this first generation tech bio companies who claim that hey, with AI we can do new things like enabling technology.
00:14:48.000 --> 00:14:55.360
You know, you weren't able to do these things before, now you can, especially in the early drug discovery and development stage, which is great.
00:14:55.519 --> 00:14:57.840
Like more options is good for everyone.
00:14:58.080 --> 00:15:06.960
So not much of a disruption of what's happening, it's more like maybe expanding the possibility
of the you know treatments for patients.
00:15:07.679 --> 00:15:23.279
While these companies have failed though, especially the ones who raise a lot of money went public, and then there were big expectations from them to carry that scale of, hey, with the same resources, we can do 100 programs where a traditional biotech end only three.
00:15:23.440 --> 00:15:24.879
That's very appealing, right?
00:15:25.039 --> 00:15:26.559
But then what happened?
00:15:26.799 --> 00:15:28.240
It did not translate.
00:15:28.399 --> 00:15:35.759
You know, they had to maybe bring only one of these programs or two of them to the clinic, very much like a traditional biotech.
00:15:35.919 --> 00:15:42.320
So that actually crashed and burned a lot of faith and belief in this kind of tech biocompanies.
00:15:42.559 --> 00:15:47.840
And that happened for many reasons, but one of them is the biologic is super complex.
00:15:48.159 --> 00:15:58.000
So there is this second, what I'm gonna call it second generation tech biocompanies who realize that and approach it from two angles.
00:15:58.240 --> 00:16:03.120
One of them is trying to understand the biology upstream.
00:16:03.279 --> 00:16:16.480
So there are foundational models trying to understand how the disease state is different than the healthy state, and how you need to how your molecule is going to operate within that state and change it.
00:16:17.279 --> 00:16:24.159
And then these AI companies, tech biocompanies are in its essences are now data companies.
00:16:24.320 --> 00:16:28.240
The model differentiation is getting very, very small over time.
00:16:28.399 --> 00:16:34.000
How you use it is still matters, but you know, every couple of months a new model comes up.
00:16:34.240 --> 00:16:39.360
Unfortunately, where these molecules fail is the toxicity and the efficacy.
00:16:39.600 --> 00:16:41.919
And those essays are not high throughput.
00:16:42.000 --> 00:16:47.120
So there is not a lot of data for the models to learn or to predict against.
00:16:48.159 --> 00:16:56.559
I think you will see the second generation tech biocompanies to put a lot of capital into solving that problem.
00:16:57.120 --> 00:17:05.440
I think AI is good enough to capture the complexity of the biology to an extent when there's sufficient data.
00:17:05.519 --> 00:17:14.079
So you see that the parties will be building more foundational models and high-throughput assays, downstream essays to capture that.
00:17:14.480 --> 00:17:27.279
But even then, what you have built is a bunch of molecules against different diseases ready to go into clinic, but you still go through that 10 years, 12 years clinical journey.
00:17:28.559 --> 00:17:39.200
I think, however, there's a uh I mean this is the idea is not new, but it is becoming more realistic.
00:17:39.519 --> 00:17:43.279
Not sure if the 2030 is the time frame for that.
00:17:43.759 --> 00:17:49.359
Um the process approval rather than a product approval.
00:17:49.519 --> 00:17:57.119
So it happened with CARTE's, it was happening with the oligoantisense oligonucleotides uh in the UK.
00:17:57.279 --> 00:18:07.039
So you you are basically saying to the regulatory agency that do not approve the thing that I produce, approve the way how I produce it.
00:18:07.359 --> 00:18:11.519
So you will still go through that 10-12 years process, but you will go on the US.
00:18:12.160 --> 00:18:18.640
And then everything that you produce will have the right efficacy and toxicity profile on paper according to the theory.
00:18:18.960 --> 00:18:21.359
So that doesn't need additional testing.
00:18:21.519 --> 00:18:26.400
And maybe you also produce those molecules to a much smaller population.
00:18:26.640 --> 00:18:33.200
So the risk of side effect is kind of contained within that population, too.
00:18:33.920 --> 00:18:43.359
Uh, for me, that's the third generation of tech biocompanies who made a big difference in the clinical trial space and ideally unify it.
00:18:43.519 --> 00:18:48.400
You go through that once and then build something really, really massive in value.
00:18:48.640 --> 00:18:50.160
I think it's all play out.
00:18:50.400 --> 00:18:52.960
Uh, I cannot say if it's five years, ten or more.
00:18:53.200 --> 00:19:00.400
I'm interested to see what you think because some of the largest Series A funding rounds in the last 12 to 18 months have been the tech biospace.
00:19:00.640 --> 00:19:03.359
But I what we see is we start to see emerging markets.
00:19:03.440 --> 00:19:05.279
So Paris is a good example within Europe.
00:19:05.359 --> 00:19:10.000
Paris is quite a force in that space, but it's not necessarily a force for traditional biotech.
00:19:10.480 --> 00:19:15.599
Where do you see as like the hotspots for for tech biocompanies globally at the moment?
00:19:16.160 --> 00:19:18.799
It's still for me Silicon Valley.
00:19:18.880 --> 00:19:18.960
Yeah.
00:19:20.559 --> 00:19:23.759
And the reason is so please check the numbers.
00:19:23.920 --> 00:19:39.359
But uh last time when I had a look at it, um Boston was having like one third of one-third of um all biotech investments, something like that in the world.
00:19:39.839 --> 00:19:42.880
And and San Francisco takes even more than that.
00:19:43.920 --> 00:19:52.319
But it it is not known necessarily only for biotechs because they do a lot of other things that turn into one trillion dollar companies.
00:19:52.880 --> 00:19:55.920
So and it is not a nationalistic thing.
00:19:56.240 --> 00:20:07.279
I'm not saying that, hey, Americans are the best, but it you know, people go there because the the support network is there, the funds are there, the resources are there.
00:20:07.440 --> 00:20:12.079
Um, many of their RD teams might be elsewhere in in Europe.
00:20:12.559 --> 00:20:24.799
I mean, interestingly, uh and these people, some of these very, you know, you said that in in tech biospace, you you see these larger rounds, maybe you know, 80 million, 200 million and so on.
00:20:25.039 --> 00:20:27.279
Um the teams are not that big.
00:20:27.519 --> 00:20:34.400
30 people, 40 people, and you find them completely um distributed around the world.
00:20:34.640 --> 00:20:38.319
And uh you find them wherever they are and bring into the company.
00:20:38.480 --> 00:20:43.839
I don't I mean the capital is still acting in the US predominantly.
00:20:44.400 --> 00:20:49.920
But the the expert uses somewhat distributed all around the world.
00:20:50.160 --> 00:20:51.519
I think that mirrors what we see.
00:20:51.599 --> 00:20:59.440
So the Boston-based interesting table, there's 1,400 roughly biotechs if you wrap in the whole industry in Massachusetts.
00:20:59.599 --> 00:21:02.240
You compare it to Europe, and there's 1,400 in the whole of Europe.
00:21:02.400 --> 00:21:13.680
And so I think the advantage of having the ecosystem, you've got MIT, Harvard, like all centered around one location with investors, with the support network, the ecosystem.
00:21:14.079 --> 00:21:16.640
You can see why it still has the opportunity to thrive.
00:21:16.799 --> 00:21:18.799
But yeah, it's uh I'm excited.
00:21:19.200 --> 00:21:22.640
Tech bio is our fastest growing part of our business in terms of what we do.
00:21:22.799 --> 00:21:37.519
Um and the skill sets, that the only thing I worry about for the future is how do you attract some of the, particularly if you look to the more of a traditional AI skill set of someone who's building the LLM, for example, building the model, the multimodal model, trying to attract someone from NVIDIA.
00:21:38.240 --> 00:21:50.960
Our industry just does not pay what we need to pay to attract someone who's coming from tech, or even in some cases, we then look further down the line, attracting someone who's joining from automotive where the salaries are out of kilter.
00:21:51.039 --> 00:21:54.799
So I still wonder how we keep up the demand for talent in the future.
00:21:54.880 --> 00:21:59.839
But yeah, I mean again, the if you have bills.
00:22:00.240 --> 00:22:02.960
A company with 1,000, 2,000, maybe more people.
00:22:03.039 --> 00:22:11.039
Yes, you need to expand your pool to bring people who are maybe incentivized more about money than other things.
00:22:11.200 --> 00:22:18.240
But I believe we were paying originally under market rates, below market rates.
00:22:18.400 --> 00:22:25.920
But we had this six-monthly review for uh pay and performance to bring everybody to the market level and above.
00:22:26.640 --> 00:22:31.119
But I that was never, I think, the selling factor for Antours.
00:22:32.400 --> 00:22:38.319
You could hear from the candidates' voice that they are excited about what we do, right?
00:22:38.559 --> 00:22:47.440
And they are willing to uproot their family, move to Cardiff, and then you know re-establish their life and give this a shot with a lot of risk involved.
00:22:47.680 --> 00:22:55.519
And some people are built for it and they like it, or they're in the right time in
their life to take on a challenge like that.
00:22:55.839 --> 00:23:00.799
By just paying more, I don't think you would get the people that you necessarily need.
00:23:00.960 --> 00:23:10.000
But um it it needs to be the right values, the the right mission, and and of course you still need to uh compensate them fairly.
00:23:10.640 --> 00:23:21.440
That purpose, the impact, the the patient impact that really we can have in our sector that you can't get in other sectors, which is is so so vital for people and and and what you need to search for.
00:23:21.599 --> 00:23:23.359
So completely agree with you on that.
00:23:23.920 --> 00:23:28.000
Finally, um, by the way, thank you for sharing, thank you for your openness.
00:23:28.160 --> 00:23:29.359
Uh, I really appreciate it.
00:23:29.599 --> 00:23:32.640
I'd like to finish with two pieces of advice.
00:23:32.799 --> 00:23:39.599
Uh, you're a founder, uh, you've been through, I think you said 10 years coming up, so you've been through a real journey.
00:23:39.920 --> 00:23:42.160
What two pieces of advice would you give?
00:23:42.319 --> 00:23:46.640
Um, I'm uh uh I'm looking to set up my own organization.
00:23:46.880 --> 00:23:50.640
What are you gonna give me uh that you've learned over the last 10 years?
00:23:51.039 --> 00:23:58.559
What I would recommend was, I mean, it's gonna be, I'm sure there are exceptions, but it's gonna be a very difficult, very long journey.
00:23:58.720 --> 00:24:08.319
So, unless you are in it for uh something that is dear to your heart, it's gonna be very, very challenging periods.
00:24:08.559 --> 00:24:10.240
So find that.
00:24:10.319 --> 00:24:24.240
I think find that passion that's what will get you through and make it in a verse while so when we when we incorporated the non-tverse, we could we got a little bit of funding and we ran out of that very, very quickly.
00:24:24.559 --> 00:24:29.200
I think um so there were periods where we couldn't do payroll.
00:24:29.359 --> 00:24:34.960
I mean, it never happened to our team, but it definitely happened to funders in the early years.
00:24:35.200 --> 00:24:45.279
And I due to the lack of financial stability or buffer support, maybe you are forced to take deals that you wouldn't take otherwise.
00:24:45.680 --> 00:24:59.359
Um so if you have the option, I think it is good to maybe stick to your day job and put aside capital for six months or a bit more before you give it a go.
00:24:59.759 --> 00:25:01.039
Really great advice.
00:25:01.279 --> 00:25:02.559
Thank you so much.
00:25:02.880 --> 00:25:03.759
Thanks for listening.
00:25:03.920 --> 00:25:14.079
We hope today's conversation sparked your interest and more importantly, left you with a few key takeaways you can use to help shape your organization or your own experience looking ahead.
00:25:14.319 --> 00:25:20.799
If you found it valuable, please like and share the episode, and we genuinely love to hear your comments and perspectives.
00:25:20.960 --> 00:25:26.720
Don't forget to subscribe if you like, and we will see you next time on the Beyond the Purpose podcast.